William Blair Analysts Lift Earnings Estimates for MRSN

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – William Blair increased their Q2 2025 earnings per share (EPS) estimates for Mersana Therapeutics in a note issued to investors on Thursday, May 15th. William Blair analyst A. Hsieh now forecasts that the company will post earnings per share of ($0.18) for the quarter, up from their previous forecast of ($0.21). William Blair has a “Outperform” rating on the stock. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. William Blair also issued estimates for Mersana Therapeutics’ Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.76) EPS.

Mersana Therapeutics (NASDAQ:MRSN) last issued its earnings results on Thursday, May 15th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.02. The firm had revenue of $2.75 million during the quarter, compared to analysts’ expectations of $6.05 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%.

Several other brokerages have also recently commented on MRSN. Guggenheim reaffirmed a “buy” rating and issued a $5.00 target price on shares of Mersana Therapeutics in a research report on Friday. Wedbush reaffirmed an “outperform” rating and issued a $3.00 target price on shares of Mersana Therapeutics in a research report on Thursday. Finally, Truist Financial raised their target price on Mersana Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $5.20.

Mersana Therapeutics Stock Up 8.1%

Shares of MRSN stock opened at $0.34 on Monday. The stock has a market cap of $42.39 million, a P/E ratio of -0.56 and a beta of 1.32. Mersana Therapeutics has a one year low of $0.26 and a one year high of $2.83. The stock has a fifty day moving average price of $0.37 and a 200 day moving average price of $1.00. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35.

Institutional Trading of Mersana Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in MRSN. Pallas Capital Advisors LLC acquired a new stake in shares of Mersana Therapeutics in the first quarter valued at $33,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Mersana Therapeutics in the fourth quarter valued at $37,000. Invesco Ltd. increased its stake in shares of Mersana Therapeutics by 109.3% in the first quarter. Invesco Ltd. now owns 114,863 shares of the company’s stock valued at $40,000 after buying an additional 59,991 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Mersana Therapeutics in the first quarter valued at $45,000. Finally, Algert Global LLC increased its position in Mersana Therapeutics by 124.7% in the first quarter. Algert Global LLC now owns 135,013 shares of the company’s stock worth $46,000 after purchasing an additional 74,930 shares during the period. 93.92% of the stock is currently owned by institutional investors and hedge funds.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.